Starting August with a bang, Roche has entered into two deals with Poseida Therapeutics and Kiniksa Pharmaceuticals to bolster its oncology and inflammatory disease pipelines. The latter deal involves Roche committing US$100 M upfront for the rights to develop and commercialise vixarelimab in fibrosis, an antibody targeting oncostatin M receptor beta. Additionally, Roche is also paying Poseida US$110 M upfront for rights to and options on allogeneic chimeric antigen receptor T cells (CAR-T) therapies directed to haematologic malignancies.